Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 895-902

  Welsh, James W ^a   Komaki, Ritsuko ^a   Amini, Arya ^a   Munsell, Mark F ^a   Unger, Wyatt ^a   Allen, Pamela K ^a   Chang, Joe Y ^a   Wefel, Jeffrey S ^a   McGovern, Susan L ^a   Garland, Linda L ^b   Chen, Su S ^a   Holt, Jamie ^b   Liao, Zhongxing ^a   Brown, Paul ^a   Sulman, Erik ^a   Heymach, John V ^a   Kim, Edward S ^a   Stea, Baldassarre ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ACNE; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COUGHING; CRANIOTOMY; DEHYDRATION; DEMENTIA; DIARRHEA; DIZZINESS; DNA SEQUENCE; DRUG DOSE REDUCTION; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUTATION; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; RADIATION NECROSIS; RASH; SCORING SYSTEM; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TASTE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WHOLE BRAIN RADIATION THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84875720245     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1174     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010.
2. Mujoomdar A, Austin JH, Malhotra R, et al: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: Primary tumor size, cell type, and lymph node metastases. Radiology 242:882-888, 2007.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865-2872, 2004.
4. Verger E, Gil M, Yaya R, et al: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185- 191, 2005.
5. Sperduto PW, Berkey B, Gaspar LE, et al: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1, 960 patients in the RTOG Database. Int J Radiat Oncol Biol Phys 70:510-514, 2008.
6. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
7. Knisely JP, Berkey B, Chakravarti A, et al: A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 71:79-86, 2008.
8. McHaffie DR, Chabot P, Dagnault A, et al: Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of = 6 brain metastases: A multi-institutional phase II trial. J Neurooncol 105:301-308, 2011.
9. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
10. Neal JW: The SATURN trial: The value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol 6:1827-1832, 2010.
11. Roberts PJ, Stinchcombe TE, Der CJ, et al: Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28:4769-4777, 2010.
12. Chinnaiyan P, Huang S, Vallabhaneni G, et al: Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328-3335, 2005.
13. Chen DJ, Nirodi CS: The epidermal growth factor receptor: A role in repair of radiationinduced DNA damage. Clin Cancer Res 13:6555- 6560, 2007.
14. Akimoto T, Hunter NR, Buchmiller L, et al: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884-2890, 1999.
15. Togashi Y, Masago K, Fukudo M, et al: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5:950-955, 2010.
16. Weber B, Winterdahl M, Memon A, et al: Erlotinib accumulation in brain metastases from non-small cell lung cancer: Visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6:1287-1289, 2011.
17. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44:265-276, 2005.
18. Correa DD, DeAngelis LM, Shi W, et al: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548-555, 2004.
19. Correa DD, Rocco-Donovan M, DeAngelis LM, et al: Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 91: 315-321, 2009.
20. Hottinger AF, DeAngelis LM, Yahalom J, et al: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69: 1178-1182, 2007.
21. Chao JH, Phillips R, Nickson JJ: Roentgen-ray therapy of cerebral metastases. Cancer 7:682-689, 1954.
22. Folstein MF, Folstein SE, McHugh PR: "Minimental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975.
23. European Organisation for Research and Treatment of Cancer: Common Toxicity Criteria (CTC). http://www.eortc.be/services/doc/ctc/default.htm.
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
25. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999.
26. Jason PF, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999.
27. Wefel JS, Cloughesy T, Zazzali JL, et al: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660-668, 2011.
28. Mehta MP, Rodrigus P, Terhaard CH, et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529-2536, 2003.
29. Sperduto PW, Chao ST, Sneed PK, et al: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4, 259 patients. Int J Radiat Oncol Biol Phys 77:655-661, 2010.
30. Matsumoto S, Takahashi K, Iwakawa R, et al: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119:1491-1494, 2006.